ArticleAnnals of surgical oncology2024
Universal Germline-Genetic Testing for Breast Cancer: Implementation in a Rural Practice and Impact on Shared Decision-Making.
Article in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.
- Short-term Patient-Reported Outcomes Following Bilateral Risk-Reducing Mastectomy for Patients at a High Risk for Breast Cancer: A Systematic Review.Annals of surgical oncology · 2025Pooled it
- Trial
- Genetic Testing Uptake Among Patients With Newly Diagnosed Breast Cancer.JAMA network open · 2026Article
- Risk-Reducing Interventions in Women With Pathogenic Variants in Breast Cancer Susceptibility Genes.JCO precision oncology · 2026Article
- Are Broadened Guidelines Improving our Detection of Pathologic Genetic Mutations in Breast Cancer Patients? A 5-Year Comparative Analysis of American Society of Breast Surgeons and National Comprehensive Cancer Network Guidelines.Annals of surgical oncology · 2025Article
- Prevalence of BRCA1 and BRCA2 Variants in an Unselected Population of Women With Breast Cancer.JAMA network open · 2025Article
- The association of race and ethnicity with risk-reducing mastectomies in patients with non-BRCA mutations.American journal of surgery · 2025Article
- Germline genetic mutations in a multi-center cohort of 248 phyllodes tumors.Breast cancer research and treatment · 2025Article
- Interdisciplinary Implementation of a Synoptic Reporting Template for Melanoma Nodal Surveillance Ultrasound.Annals of surgical oncology · 2024Article
- Screening guidelines for individuals at increased risk for prostate cancer.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2024Review
- Universal Genetic Testing for Newly Diagnosed Invasive Breast Cancer.JAMA network open · 2024Article
- Clinical genetics in breast cancer.Journal of surgical oncology · 2024Review
- Genetic literacy among surgeons who manage patients with cancer: a national survey of knowledge, perceptions, attitudes, and barriers.Canadian journal of surgery. Journal canadien de chirurgieArticle
Corrections and comments
- Commented on by
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhereas the National Comprehensive Cancer Network (NCCN) criteria restrict germline-genetic testing (GGT) to a subset of breast cancer (BC) patients, the American Society of Breast Surgeons recommends universal GGT. Although the yield of pathogenic germline variants (PGV) in unselected BC patients has been studied, the practicality and utility of incorporating universal GGT into routine cancer care in community and rural settings is understudied. This study reports real-world implementation of universal GGT for patients with breast cancer and genetics-informed, treatment decision-making in a rural, community practice with limited resources.
methodsFrom 2019 to 2022, all patients with breast cancer at a small, rural hospital were offered GGT, using a genetics-extender model. Statistical analyses included Fisher's exact test, t-tests, and calculation of odds ratios. Significance was set at p < 0.05.
resultsOf 210 patients with breast cancer who were offered GGT, 192 (91.4%) underwent testing with 104 (54.2%) in-criteria (IC) and 88 (45.8%) out-of-criteria (OOC) with NCCN guidelines. Pathogenic germline variants were identified in 25 patients (13.0%), with PGV frequencies of 15 of 104 (14.4%) in IC and ten of 88 (11.4%) in OOC patients (p = 0.495). GGT informed treatment for 129 of 185 (69.7%) patients.
conclusionsUniversal GGT was successfully implemented in a rural, community practice with > 90% uptake. Treatment was enhanced or de-escalated in those with and without clinically actionable PGVs, respectively. Universal GGT for patients with breast cancer is feasible within rural populations, enabling optimization of clinical care to patients' genetic profile, and may reduce unnecessary healthcare, resource utilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.